Androgen receptor attenuation of Ad5 replication: Implications for the development of conditionally replication competent adenoviruses

Naseruddin Höti, Ying Li, Chien Lun Chen, Wasim H. Chowdhury, David C. Johns, Qinghua Xia, Arup Kabul, Jer Tsong Hsieh, Michael Berg, Gary Ketner, Shawn E. Lupold, Ronald Rodriguez

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Conditionally replication competent adenoviruses (CRAds) represent one of the most intensely studied gene therapy strategies for a variety of malignancies, including prostate cancer. These viruses can be generated by placing a tissue or cancer-specific promoter upstream of one or more of the viral genes required for replication (e.g., E1A, E1B). We report here that E1A inhibits androgen receptor (AR) target gene induction and, correspondingly, activated AR inhibits adenoviral replication. This mutual inhibition appears to be an indirect effect, possibly through competition for shared transcriptional co-activators. The net effect is that the oncolytic effect of prostate-specific CRAds is attenuated by these interactions. Fusion of the E1A to AR ameliorates this inhibition, while enhancing specificity. These findings have significant implications in the development of prostate-specific CRAd therapies.

Original languageEnglish (US)
Pages (from-to)1495-1503
Number of pages9
JournalMolecular Therapy
Volume15
Issue number8
DOIs
StatePublished - Aug 2007

Fingerprint

Androgen Receptors
Adenoviridae
Prostate
Viral Genes
Genetic Therapy
Neoplasms
Prostatic Neoplasms
Viruses
Genes
Therapeutics

ASJC Scopus subject areas

  • Molecular Biology

Cite this

Androgen receptor attenuation of Ad5 replication : Implications for the development of conditionally replication competent adenoviruses. / Höti, Naseruddin; Li, Ying; Chen, Chien Lun; Chowdhury, Wasim H.; Johns, David C.; Xia, Qinghua; Kabul, Arup; Hsieh, Jer Tsong; Berg, Michael; Ketner, Gary; Lupold, Shawn E.; Rodriguez, Ronald.

In: Molecular Therapy, Vol. 15, No. 8, 08.2007, p. 1495-1503.

Research output: Contribution to journalArticle

Höti, N, Li, Y, Chen, CL, Chowdhury, WH, Johns, DC, Xia, Q, Kabul, A, Hsieh, JT, Berg, M, Ketner, G, Lupold, SE & Rodriguez, R 2007, 'Androgen receptor attenuation of Ad5 replication: Implications for the development of conditionally replication competent adenoviruses', Molecular Therapy, vol. 15, no. 8, pp. 1495-1503. https://doi.org/10.1038/sj.mt.6300223
Höti, Naseruddin ; Li, Ying ; Chen, Chien Lun ; Chowdhury, Wasim H. ; Johns, David C. ; Xia, Qinghua ; Kabul, Arup ; Hsieh, Jer Tsong ; Berg, Michael ; Ketner, Gary ; Lupold, Shawn E. ; Rodriguez, Ronald. / Androgen receptor attenuation of Ad5 replication : Implications for the development of conditionally replication competent adenoviruses. In: Molecular Therapy. 2007 ; Vol. 15, No. 8. pp. 1495-1503.
@article{a40d3b90fb2540d9ab15d6aca65cc10f,
title = "Androgen receptor attenuation of Ad5 replication: Implications for the development of conditionally replication competent adenoviruses",
abstract = "Conditionally replication competent adenoviruses (CRAds) represent one of the most intensely studied gene therapy strategies for a variety of malignancies, including prostate cancer. These viruses can be generated by placing a tissue or cancer-specific promoter upstream of one or more of the viral genes required for replication (e.g., E1A, E1B). We report here that E1A inhibits androgen receptor (AR) target gene induction and, correspondingly, activated AR inhibits adenoviral replication. This mutual inhibition appears to be an indirect effect, possibly through competition for shared transcriptional co-activators. The net effect is that the oncolytic effect of prostate-specific CRAds is attenuated by these interactions. Fusion of the E1A to AR ameliorates this inhibition, while enhancing specificity. These findings have significant implications in the development of prostate-specific CRAd therapies.",
author = "Naseruddin H{\"o}ti and Ying Li and Chen, {Chien Lun} and Chowdhury, {Wasim H.} and Johns, {David C.} and Qinghua Xia and Arup Kabul and Hsieh, {Jer Tsong} and Michael Berg and Gary Ketner and Lupold, {Shawn E.} and Ronald Rodriguez",
year = "2007",
month = "8",
doi = "10.1038/sj.mt.6300223",
language = "English (US)",
volume = "15",
pages = "1495--1503",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "8",

}

TY - JOUR

T1 - Androgen receptor attenuation of Ad5 replication

T2 - Implications for the development of conditionally replication competent adenoviruses

AU - Höti, Naseruddin

AU - Li, Ying

AU - Chen, Chien Lun

AU - Chowdhury, Wasim H.

AU - Johns, David C.

AU - Xia, Qinghua

AU - Kabul, Arup

AU - Hsieh, Jer Tsong

AU - Berg, Michael

AU - Ketner, Gary

AU - Lupold, Shawn E.

AU - Rodriguez, Ronald

PY - 2007/8

Y1 - 2007/8

N2 - Conditionally replication competent adenoviruses (CRAds) represent one of the most intensely studied gene therapy strategies for a variety of malignancies, including prostate cancer. These viruses can be generated by placing a tissue or cancer-specific promoter upstream of one or more of the viral genes required for replication (e.g., E1A, E1B). We report here that E1A inhibits androgen receptor (AR) target gene induction and, correspondingly, activated AR inhibits adenoviral replication. This mutual inhibition appears to be an indirect effect, possibly through competition for shared transcriptional co-activators. The net effect is that the oncolytic effect of prostate-specific CRAds is attenuated by these interactions. Fusion of the E1A to AR ameliorates this inhibition, while enhancing specificity. These findings have significant implications in the development of prostate-specific CRAd therapies.

AB - Conditionally replication competent adenoviruses (CRAds) represent one of the most intensely studied gene therapy strategies for a variety of malignancies, including prostate cancer. These viruses can be generated by placing a tissue or cancer-specific promoter upstream of one or more of the viral genes required for replication (e.g., E1A, E1B). We report here that E1A inhibits androgen receptor (AR) target gene induction and, correspondingly, activated AR inhibits adenoviral replication. This mutual inhibition appears to be an indirect effect, possibly through competition for shared transcriptional co-activators. The net effect is that the oncolytic effect of prostate-specific CRAds is attenuated by these interactions. Fusion of the E1A to AR ameliorates this inhibition, while enhancing specificity. These findings have significant implications in the development of prostate-specific CRAd therapies.

UR - http://www.scopus.com/inward/record.url?scp=34547131558&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547131558&partnerID=8YFLogxK

U2 - 10.1038/sj.mt.6300223

DO - 10.1038/sj.mt.6300223

M3 - Article

C2 - 17565351

AN - SCOPUS:34547131558

VL - 15

SP - 1495

EP - 1503

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 8

ER -